Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose versus standard-dose apixaban with ticagrelor after PCI in atrial fibrillation
ISRCTN16600368Phase 4Recruiting
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of apixaban and ticagrelor in Atrial fibrillation (AFib) and coronary arteriosclerosis (2 arms), sponsored by Sheffield Teaching Hospitals NHS Foundation Trust. Primary endpoint: Bleeding time test. Started Mar 2026; status: recruiting.
02
Drugs
apixabanticagrelor
03
Conditions
Atrial fibrillation (AFib)coronary arteriosclerosis
Beyond the preview
Go deeper on ISRCTN16600368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16600368.